|
Oxford BioMedica PLC on Wednesday said it has signed a new commercial supply deal with Bristol-Myers Squibb Co. The Oxford, England-based gene and cell therapy developer has partnered with the Lawrenceville, New Jersey-based pharmaceutical maker since 2020. The latest five-year agreement sees Oxford BioMedica providing lentiviral vectors for Bristol-Myers’s CAR-T programmes, ‘subject to regulatory approval of the relevant CAR-T products’. CAR-T cell treatment is a type of immunotherapy which targets blood cancer. Vectors can convert normal T cells into CAR-T cells, which are given to patients via chemotherapy. Commercial manufacturing of the vectors is slated to start this year at Oxford BioMedica’s sites in England and in Durham, North Carolina. Oxford BioMedica didn’t provide financial details for the contract, though it said it offers potential for ‘meaningful multi-year revenue’ in support of its existing medium-term financial guidance. The contract has a five-year initial term with the option to extend. Oxford BioMedica shares were up 2.4% at 838.00 pence on Wednesday morning in London. ‘The transition from clinical to commercial manufacturing with BMS marks an important milestone for both companies,’ noted Sebastien Ribault, chief business officer at Oxford BioMedica. ‘Having supported these potentially life-saving CAR-T programmes through development, we are confident in their commercial success and look forward to continuing our partnership with BMS.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
